

Genmab

The danish king of antibodies

- A leading company in the development of monoclonal antibodies as active ingredients of drugs
- Darzalex (commercial partner J&J): one of the biggest commercial and medical success stories in biotech. Indication multiple myeloma (plasma cell carcinoma)
- Other commercial products: Kesimpta ofatumumab in the indication multiple sclerosis (partner Novartis), Tepezza teprotumumab in the indication endocrine ophthalmopathy
- Broad product pipeline with next generation antibody technologies (bispecific antibodies, antibody-drug conjugates, hexabodies)



*Tisotumab vedotin
(antibody conjugate),
in collaboration with
Seagen*



*Epcoritamab (next
generation bispecific
antibody),
in collaboration with Abbvie*

ESG Risk Rating

27.2

- Negligible
- Low
- **Medium**
- High
- Severe

UN Global Compact

- **Compliant**
- Watchlist
- Non-compliant

Controversy scale

0

- Low
- Moderate
- **Significant**
- High
- Severe

Controversial business areas

- **Animal testing***
- *Pharmaceutical products, medical devices and biotechnology (no cosmetics)

For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities.

Source: Genmab, Bellevue Asset Management, Sustainalytics, May 2021